Oak Hill Bio is committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.
About Us
Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. Oak Hill was created to advance a pipeline of promising clinical and preclinical investigational therapeutics and deliver innovation to a challenging drug development space that has seen little progress over the last two decades. Our team combines rare disease and neonatology expertise with the experience and acumen required to bring novel medicines through regulatory approval and, ultimately, to the patients who need them.
Pipeline
Our pipeline includes two clinical-stage and four preclinical-stage programs aimed at addressing complications of extremely preterm birth and rare autoimmune diseases. Our lead therapeutic candidate, OHB-607, targets complications in extremely premature babies, an underserved population with significant developmental challenges. OHB-607 is currently in a Phase 2b trial: https://www.clinicaltrials.gov/study/NCT03253263. OHB-101 has the potential to improve the conditions for many with autoimmune diseases.
